Trial Profile
A double-blind, randomized, placebo and active-controlled, six-period crossover study to evaluate the likeability, safety, and abuse liability of NRP104 [lisdexamfetamine] in healthy adult volunteers with histories of stimulant abuse
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2009
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary) ; Amfepramone; Amfetamine
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacodynamics
- Sponsors New River Pharmaceuticals
- 21 Oct 2006 New trial record.